Ulviprubart

Therini Bio's novel monoclonal antibody THN391, targeting fibrin-driven neuroinflammation, demonstrated positive safety and tolerability results in Phase 1a trials with healthy volunteers.

Isomorphic Labs raised $600 million in its first external funding round in March 2025, representing the largest private biotech investment of the month.

Abcuro raises $200 million in Series C financing to support Phase II/III MUSCLE clinical trial of ulviprubart, targeting inclusion body myositis through KLRG1 inhibition.

Abcuro has raised $200 million in Series C financing led by NEA to advance ulviprubart, a first-in-class monoclonal antibody treatment for inclusion body myositis (IBM).